Gossamer Bio Inc (GOSS) is a clinical-stage biopharmaceutical company focused on developing drug candidates for serious diseases. The company generates no product revenue, funding operations through collaboration agreements and capital markets activity. As of December 31, 2025, Gossamer carried accrued research and development expenses of $21.7 million, reflecting active third-party clinical trial and contractor activity. Its lead program is seralutinib, which remains under regulatory review for potential marketing approval. General and administrative expenses include costs for executive, finance, legal, accounting, insurance, and commercial planning functions. The company holds long-term convertible senior notes on its balance sheet and has an accumulated deficit, consistent with a pre-revenue drug development operation. CEO Faheem Hasnain signed the 10-K filed March 17, 2026, indicating his continued leadership. The company operates under U.S. securities exchange listing requirements and is subject to HIPAA, GDPR, and other healthcare and data privacy regulations affecting its clinical operations.

Revenue model

Gossamer Bio has no product revenue. It records receivables from collaboration agreements as its primary near-term cash source, alongside proceeds from equity and convertible debt issuances. The company accrues R&D expenses as services are rendered by third-party contractors, clinical trial sites, and laboratories.

Products and services

Seralutinib is the disclosed lead drug candidate. The company conducts clinical trials through third-party contract research organizations, laboratories, and participating clinical trial sites.

Customers and end markets

The filing does not disclose specific customers or commercial end markets. The company is pre-commercial, with end-market exposure contingent on seralutinib receiving marketing approval.

Value-chain role

Gossamer Bio operates as a drug developer, outsourcing clinical execution to third-party contractors and clinical trial sites while retaining internal R&D oversight, regulatory strategy, and commercial planning functions.

Geographic exposure

The company is subject to U.S. regulations including HIPAA and SEC requirements, and to EU and UK GDPR, indicating clinical or operational activity touching European jurisdictions. Specific country-level revenue or site counts are not disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-17

Industry: Pharmaceutical Preparations Peers: Vericel Corp CHINOOK THERAPEUTICS, INC. Arcutis Biotherapeutics Inc Avid Bioservices, Inc. Kyntra Bio Inc Kymera Therapeutics Inc Rhythm Pharmaceuticals Inc Sana Biotechnology Inc Zentalis Pharmaceuticals Inc